Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 0.73 |
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | PPIA | P62937 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5755659 | 0.98 | LTA4H (0.96) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2655772 | 0.98 | LTA4H (0.96) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6238398 | 0.91 | LTA4H (0.82) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23631385 | 0.87 | LTA4H (0.77) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23631386 | 0.86 | LTA4H (0.74) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6079578 | 0.86 | LTA4H (0.75) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL10560686 | 0.84 | LTA4H (0.73) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23631387 | 0.84 | LTA4H (0.73) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29857565 | 0.84 | LTA4H (0.73) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3501194 | 0.84 | LTA4H (0.73) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 613 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777131-B | Synthesis method of paliperidone and key intermediate thereof | 合肥华方医药科技有限公司 | 2024-06-11 | — | — | CN | claimed |
| CN-117777131-A | Synthesis method of paliperidone and key intermediate thereof | 合肥华方医药科技有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-117024408-A | 1,2, 3-triaryl substituted benzo [ f ] isoindole-4, 9-dione compound and preparation method and application thereof | 湘潭大学 | 2023-11-10 | — | — | CN | claimed |
| US-11629155-B2 | Small molecule antagonist compound TAC5 series having toll-like receptor 3/7/8/9 inhibitory function | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2023-04-18 | — | — | US | claimed |
| US-20210214372-A1 | SMALL MOLECULE ANTAGONIST COMPOUND TAC5 SERIES HAVING TOLL-LIKE RECEPTOR 3/7/8/9 INHIBITORY FUNCTION | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2021-07-15 | — | — | US | claimed |
| CN-107311998-B | A kind of preparation method of high-purity 9-hydroxy-risperidone intermediate | 济南康和医药科技有限公司 | 2019-05-14 | — | — | CN | claimed |
| CN-102797043-B | Medicinal molecular fragment library and construction process thereof | Tianli (Tianjin) Technology Co., Ltd. (CN) | 2015-11-25 | — | — | CN | claimed |
| CN-102797043-A | Medicinal molecular fragment library and construction method thereof | CBB NETWORK CO LTD | 2012-11-28 | — | — | CN | claimed |
| US-8242269-B2 | Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes | CIPLA LIMITED (IN) | 2012-08-14 | — | — | US | claimed |
| US-20110293889-A1 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PALIPERIDONE | MSN LABORATORIES LIMITED (IN) | 2011-12-01 | — | — | US | claimed |
| WO-2009010988-A1 | AN IMPROVED, INDUSTRIALLY VIABLE PROCESS FOR THE PREPARATION OF HIGH PURITY PALIPERIDONE | NATCO PHARMA LIMITED (IN) | 2009-01-22 | — | — | WO | claimed |
| WO-2008140646-A2 | PROCESS FOR THE SYNTHESIS OF CMHTP AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-11-20 | — | — | WO | claimed |
| US-20080214809-A1 | Process for the synthesis of CMHTP and intermediates thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-09-04 | — | — | US | claimed |
| US-20080200676-A1 | Process for the synthesis of CMHTP and intermediates thereof | TEVA PHARMACEUTICALS USA, INC. | 2008-08-21 | — | — | US | claimed |
| EP-1924583-A2 | PROCESS FOR THE SYNTHESIS OF CMHTP AND INTERMEDIATES THEREOF | Teva Pharmaceutical Industries Ltd. (IL) | 2008-05-28 | — | — | EP | claimed |
| WO-2008024415-A2 | PROCESS FOR THE SYNTHESIS OF CMHTP AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INSUSTRIES LTD. (IL) | 2008-02-28 | — | — | WO | claimed |
| CN-1164568-C | Process for condensating salicyladehyde with arylamine | 中国科学院化学研究所 | 2004-09-01 | — | — | CN | claimed |
| CN-1139606-C | Norbornene catalytic system and its preparation method and application | 中国科学院化学研究所 | 2004-02-25 | — | — | CN | claimed |
| CN-1394685-A | Norbornene catalytic system and its preparation method and application | CHINESE ACAD INST CHEMISTRY (CN) | 2003-02-05 | — | — | CN | claimed |
| CN-1386735-A | Process for condensating salicyladehyde with arylamine | CHINESE ACAD INST CHEMISTRY (CN) | 2002-12-25 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214809-A1 | Process for the synthesis of CMHTP and intermediates thereof | HAMP, TPMT, MPHOSPH6 | LTA4H 1629/4885MAPK14 2026/4885RAB9A 2788/4885 |
| US-20080200676-A1 | Process for the synthesis of CMHTP and intermediates thereof | HAMP, DHPS, MPHOSPH6 | LTA4H 1256/4885MAPK14 2212/4885RAB9A 1797/4885 |
| US-11629155-B2 | Small molecule antagonist compound TAC5 series having toll-like receptor 3/7/8/9 inhibitory function | TLR5, TLR8, TLR9 | LTA4H 3039/4885MAPK14 450/4885RAB9A 1337/4885 |
| US-20210214372-A1 | SMALL MOLECULE ANTAGONIST COMPOUND TAC5 SERIES HAVING TOLL-LIKE RECEPTOR 3/7/8/9 INHIBITORY FUNCTION | TLR5, TLR8, TLR9 | LTA4H 3039/4885MAPK14 450/4885RAB9A 1337/4885 |
| US-20110293889-A1 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PALIPERIDONE | AVPR2, AVPR1B, AVPR1A | LTA4H 961/4885MAPK14 2900/4885RAB9A 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.